Carvedilol Tablet, Film Coated
Product Images NDC 43063-125

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 43063-125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (43063125)

Label for Carvedilol USP 12.5 mg film-coated tablets by PD-Rx Pharmaceuticals, Inc., with an NDC of 43063-125-93. The label details 180 tablets per package, includes reorder number 100640, lot number C20E56, and expiration date 07/2021. It features dosage warnings, manufacturer info from Oklahoma City, OK, and barcode and QR code markings.*

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Fig1)

A survival analysis line graph comparing mortality percentages over 21 months from the COPERNICUS intent-to-treat study. The graph shows two lines representing groups: one labeled Placebo and the other Carvedilol, with Carvedilol associated with lower mortality. The x-axis is labeled Months and the y-axis % Mortality, with a significance value of P = 0.004 indicated.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Fig2)

A forest plot titled 'Effects on Mortality for Subgroups in COPERNICUS' showing hazard ratios with confidence intervals for various subgroups including men, women, age groups, racial groups, diabetic status, ischemic conditions, heart rate, systolic blood pressure, and spironolactone use. The x-axis represents hazard ratio values from 0.0 to 2.0, with a vertical dashed line at 1.0 indicating the reference.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig3)

A survival analysis line graph titled 'Survival Analysis for CAPRICORN (Intent-to-Treat)', showing percentage mortality over 24 months. Two lines represent groups: placebo (higher mortality) and carvedilol (lower mortality). The y-axis shows % mortality from 0 to 30%, the x-axis shows months from 0 to 24. A p-value of 0.03 is noted.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig4)

A forest plot figure titled 'Effects on Mortality for Subgroups in CAPRICORN' showing hazard ratios for various patient subgroups. The subgroups include age, gender, timing post-myocardial infarction, beta blocker use, Killip classification, thrombolytic therapy, PTCA, presence of congestive heart failure, diuretic use, angina, hypertension, diabetes, heart rate, and systolic blood pressure. The horizontal axis is labeled 'Hazard Ratio' ranging from 0.4 to 1.3, with points and confidence intervals illustrating mortality effects in these subgroups.*

FDA Label Image

Chemical Structure (Carvedilol Str)

Chemical structure of Carvedilol, the active ingredient depicted with its molecular bonds and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.